EA201370078A1 - HEPATITIS C VIRUS INHIBITORS - Google Patents

HEPATITIS C VIRUS INHIBITORS

Info

Publication number
EA201370078A1
EA201370078A1 EA201370078A EA201370078A EA201370078A1 EA 201370078 A1 EA201370078 A1 EA 201370078A1 EA 201370078 A EA201370078 A EA 201370078A EA 201370078 A EA201370078 A EA 201370078A EA 201370078 A1 EA201370078 A1 EA 201370078A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
new compounds
virus inhibitors
compositions containing
compounds
Prior art date
Application number
EA201370078A
Other languages
Russian (ru)
Inventor
Маконен Белема
Хевавасам
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201370078A1 publication Critical patent/EA201370078A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к новым соединениям формулы (I), как определено в описании, и композициям, содержащим такие новые соединения. Эти соединения являются полезными противовирусными агентами, особенно в ингибировании функции белка NS5A, кодируемого вирусом гепатита С (HCV). Таким образом, изобретение также относится к способу лечения HCV зависимых заболеваний или условий путем применения этих новых соединений или композиции, содержащей такие новые соединения.The invention relates to new compounds of formula (I), as defined in the description, and compositions containing such new compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by hepatitis C virus (HCV). Thus, the invention also relates to a method for treating HCV-dependent diseases or conditions by using these new compounds or compositions containing such new compounds.

EA201370078A 2010-09-24 2010-09-24 HEPATITIS C VIRUS INHIBITORS EA201370078A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/050138 WO2012039717A1 (en) 2010-09-24 2010-09-24 Hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
EA201370078A1 true EA201370078A1 (en) 2013-11-29

Family

ID=43037168

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370078A EA201370078A1 (en) 2010-09-24 2010-09-24 HEPATITIS C VIRUS INHIBITORS

Country Status (8)

Country Link
EP (1) EP2619195A1 (en)
JP (1) JP5619289B2 (en)
CN (1) CN103249730A (en)
BR (1) BR112013008148A2 (en)
CA (1) CA2812699A1 (en)
EA (1) EA201370078A1 (en)
MX (1) MX2013002927A (en)
WO (1) WO2012039717A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
SI2628481T1 (en) 2009-06-11 2016-08-31 Abb Vie Bahamas Limited Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV
CN102656160A (en) 2009-07-16 2012-09-05 顶点制药公司 Benzimidazole analogues for the treatment or prevention of flavivirus infections
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
BR112013004520A2 (en) 2010-08-26 2016-06-07 Univ Emory potent and selective hepatitis c virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
WO2013118097A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
KR101995683B1 (en) 2012-06-04 2019-07-02 이도르시아 파마슈티컬스 리미티드 Benzimidazole-proline derivatives
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN105051040A (en) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 Azetidine amide derivatives as orexin receptor antagonists
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
PT3077391T (en) 2013-12-04 2018-11-26 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
MX2019011239A (en) 2017-03-31 2019-10-21 Syngenta Participations Ag Fungicidal compositions.
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003261434A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102004036971B4 (en) 2004-07-30 2009-07-30 Advanced Micro Devices, Inc., Sunnyvale Technique for the evaluation of local electrical properties in semiconductor devices
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010034721A (en) * 2008-07-28 2010-02-12 Fujitsu Ltd Packet capture apparatus, packet capture method, and packet capture program
NZ593808A (en) * 2008-12-03 2014-04-30 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
EP2619195A1 (en) 2013-07-31
JP2013537905A (en) 2013-10-07
CN103249730A (en) 2013-08-14
JP5619289B2 (en) 2014-11-05
BR112013008148A2 (en) 2016-08-09
MX2013002927A (en) 2013-05-30
CA2812699A1 (en) 2012-03-29
WO2012039717A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
EA201370078A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201101240A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201171152A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201270555A1 (en) COMBINATION OF HEPATITIS C VIRUS INHIBITORS
EA201390155A1 (en) COMBINATION OF HEPATITIS C VIRUS INHIBITORS
EA201001275A1 (en) CONFORMATION-LIMITED BIPHENYL DERIVATIVES FOR USE AS HEPATITIS C VIRUS INHIBITORS
EA201491361A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201270622A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201390190A1 (en) HEPATITIS C VIRUS INHIBITORS
EA200900676A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201270656A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201001273A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201491179A1 (en) 2 ', 4'-DIFFOROR-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS AN INHIBITORS REPLICATION RNA HEPATITIS C VIRUS
EA201391152A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201390538A1 (en) ANTI-VIRUS COMPOUNDS
EA201391637A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201001274A1 (en) IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS
EA201171208A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201171174A1 (en) HEPATITIS C VIRUS REPLICATION INHIBITORS
EA201101082A1 (en) HEPATITIS C VIRUS INHIBITORS
EA201370017A1 (en) HEPATITIS C VIRUS INHIBITORS
CO6190510A2 (en) HEPATITIS C VIRUS INHIBITORS
ATE469155T1 (en) CYCLOPROPYL-FUSIONED INDOLEBENZAZEPINE HCV NS5B INHIBITORS
ATE483712T1 (en) HCV NS5B INHIBITORS
NO20091845L (en) Macrocyclic peptides such as hepatitis C virus inhibitors